Abstract

According to the Indian Menopause Society's third consensus conference, India's postmenopausal women number about 43 million and are forecast to rise to 103 million by 2026. Although the average age for menopause in India is 47.5 years, there has recently been an alarming rise in premature menopause among Indian women. Menopause is experienced by nearly 4% of women in the age group of 29-34 years, and it is experienced by 8% of women in the age group of 35-39 years. Although the cause of early menopause is unknown, it is a significant public health concern because of its effect on the production of metabolic syndrome components. About the fact that HRT reduces postmenopausal risks, it is no longer prescribed for long-term usage owing to its effect on the growth of some cancers, like endometrial cancer and breast cancer, as well as its detrimental impact on cardiovascular disease. As a result, better understanding the cellular and molecular pathways involved in the pathogenesis of postmenopausal complications may contribute to new clinical therapeutic targets for their treatment. In animal models, soy isoflavones have been shown to be effective against ovariectomy (surgical menopause) and diet-induced metabolic complications; however, its effectiveness in terms of improving metabolic complications associated with postmenopausal state is largely unknown.

Keywords: Kenji Washio